
Lineage Cell Therapeutics Investor Relations Material
Latest events

Q3 2023
Lineage Cell Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from over 8,000 public companies
Lineage Cell Therapeutics, Inc., a biotechnology company, develops cell therapies for the treatment of degenerative diseases. The company develops allogeneic cellular therapies from immortally differentiated human cells. It is developing VAC, an allogeneic cancer immunotherapy for the treatment of solid tumors; OPREGEN, an allogeneic retinal pigment epithelial cell product for the treatment of dry age-related macular degeneration, as well as wet age-related macular degeneration and diabetic eye diseases; Neo-Kidney Augment, an allogeneic product candidate that is in preclinical study to treat subjects with end stage renal disease.
Latest articles

Marvel-ous Reporting: Marvel’s Comic Inspired Reports
Shareholder reports are often considered tedious and dry. However, in the late 1980s and early 1990s, Marvel Comics revolutionized this perception by transforming its financial reports into captivating comic books.
8 Dec 2023

The Payments Value Chain: A Complex Ecosystem
The payments industry is a complex and dynamic field involving multiple key players. These include customers, merchants, issuers, acquirers, card networks, and various other entities together forming the payments value chain.
8 Dec 2023

NIBE: Creating Millionaires and a Greener Future
NIBE, just like IKEA, was founded in a rural part of Sweden called Småland. The company offers a wide range of pumps, wood stoves, and solar panels.
6 Dec 2023
Ticker symbol
LCTX
Country
🇺🇸 United States